Carcinoma, Neuroendocrine - 25 Studies Found Not yet recruiting : Phase II Study of Avelumab in Metastatic Gastronetro-pancreatic (GEP) Neuroendocrine Carcinoma (NEC, WHO Grade 3) as Second-line Treatment After Failing to Etoposide+Cisplatin: Integration of Genomic Analysis to Identify Predictive Molecular Subtypes : Neuroendocrine Carcinoma, Grade 3 : 2017-05-08 : Drug: Avelumab Avelumab 10 mg/kg i.v. every 2 weeks (Q2W) Completed : S9716: Combination Chemotherapy in Treating Patients With Merkel Cell Cancer : Neuroendocrine Carcinoma of the Skin : 1999-11-01 : Drug: CMF regimen Drug: cyclophosphamide Active, not recruiting : An Open Label Registry Study of Lutetium-177 (DOTA0, TYR3) Octreotate (Lu-DOTA-TATE) Treatment in Patients With Somatostatin Receptor Positive Tumours : : 2024-05-21 Completed : Combination of Bevacizumab, Pertuzumab, and Sandostatin for Adv. Neuroendocrine Cancers : : 2024-05-21 Active, not recruiting : Octreotide Acetate and Recombinant Interferon Alfa-2b or Bevacizumab in Treating Patients With Metastatic or Locally Advanced, High-Risk Neuroendocrine Tumor : : 2024-05-21 <<< Previous